Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 28 Mar 2018 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
- 28 Mar 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 20 Oct 2017 Status changed from recruiting to active, no longer recruiting.